Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...
Daratumumab/hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone is now approved by the FDA to treat newly diagnosed multiple myeloma (MM) in patients ...
Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — Hypersensitivity reactions to injection fillers are rare and unpredictable, but when they occur, ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Findings showed patients treated with efgartigimod alfa–hyaluronidase achieved a statistically significant improvement in MGII PRO ocular scores vs placebo at week 4. Topline data were announced from ...
Silver Spring, Maryland Saturday, March 7, 2026, 11:00 Hrs [IST] ...
The FDA approved subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for induction and consolidation in ...
A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer. This is an ASCO Meeting Abstract from the ...
October 9, 2012 (Berlin, Germany) — In a randomized, double-blind, comparator-controlled, 2-way crossover trial, 2 rapid-acting insulin analogs (lispro or aspart) formulated with recombinant human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results